top of page

Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab


IDENTIFIER (ClinicalTrials.gov)NCT05142696


DRUG/TREATMENT: LUTATHERA (Lu-177 Dotatate) + Carboplatin, Etoposide, and Atezolizumab


PHASE: 1b / 2


STATUS: Recruiting


SPONSOR: Novartis Pharmaceuticals


DESCRIPTION:



Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the "Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC." Recorded: June 20, 2024


This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab. The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.


For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.


CONTACT:

Novartis Pharmaceuticals

EMAIL: novartis.email@novartis.com

PHONE: 1-888-669-6682


 

RELATED RESOURCES:


Clinical Trials Using Lutetium Lu 177 Dotatate - NCI


"High Grade Neuroendocrine Neoplasms & Small Cell Lung Cancer" with Aman Chauhan, MD

bottom of page